drugset / Trial / NCT00441870
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0225 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.
Timeline
- Start
- 2007-02
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EC0225 | Unknown | 0.38 mg | Intravenous |